================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 21, 2005
SANGAMO BIOSCIENCES, INC.
------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware
----------------------------------------------
(State or Other Jurisdiction of Incorporation)
000-30171 68-0359556
------------------------ ---------------------------------
(Commission File Number) (IRS Employer Identification No.)
501 Canal Blvd, Suite A100 Richmond, California 94804
- ----------------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
(510) 970-6000
----------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 8.01 OTHER EVENTS
On June 21, 2005, Sangamo BioSciences Inc. issued a press release
announcing that data from several of their programs to develop ZFP Therapeutics
will be presented at the third Annual Meeting of the International Society for
Stem Cell Research.
A copy of the press release issued by Sangamo BioSciences, Inc. relating to
this event is filed as an exhibit to this Current Report on Form 8-K.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits. The following material is filed as an exhibit to this Current
Report on Form 8-K:
Exhibit No.
- -----------
99.1 Press Release Issued June 21, 2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DATE: June 21, 2005
SANGAMO BIOSCIENCES, INC.
By: /s/ EDWARD O. LANPHIER II
----------------------------------
Edward O. Lanphier II
President, Chief Executive Officer
Exhibit 99.1
SANGAMO BIOSCIENCES ZFP THERAPEUTIC(TM) DATA TO BE PRESENTED AT THE 3RD ANNUAL
MEETING OF THE INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
PRESENTATIONS COVER ZFP-MEDIATED GENE REGULATION AND GENE MODIFICATION
PROGRAMS
RICHMOND, Calif., June 21 /PRNewswire-FirstCall/ -- Sangamo BioSciences,
Inc. (Nasdaq: SGMO) today announced the Company will present data from its
programs to develop novel zinc finger DNA-binding protein (ZFP) Therapeutics(TM)
at the third Annual Meeting of the International Society for Stem Cell Research
(ISSCR). The meeting will take place in San Francisco from June 23rd through
June 25th.
"Our scientists and collaborators will present data from a variety of our
programs that demonstrate the use of Sangamo's proprietary ZFP technology to
facilitate the development of novel therapeutics employing stem cells," stated
Edward Lanphier, President and CEO of Sangamo BioSciences, Inc. "We are excited
to have four presentations at the ISSCR meeting. It is an ideal forum for us to
discuss our zinc finger nuclease (ZFN)-mediated gene correction and gene
disruption data as many of the therapeutic applications of this technology will
be in hematopoietic stem cells and this meeting attracts the leaders of this
exciting and developing field."
Sangamo scientists and their collaborators will make the following
presentations; the abstract numbers, titles and presenters are listed below:
#441: Genome Editing in Human Stem Cells Using Engineered Zinc Finger
Nucleases. Angelo Lombardo, HSR-TIGET, San Raffaele Scientific
Institute, Milan, Italy
Saturday, June 25, 2005. Technology Development Plenary Session podium
presentation.
#660: Highly Efficient Endogenous Human Gene Correction Using Designed
Zinc Finger Nucleases. Michael C. Holmes, Sangamo BioSciences, Inc.
Thursday, June 23, 2005. Poster presentation.
#698: Towards Gene Correction Therapy For Wiskott-Aldrich Syndrome With
Engineered Zinc Finger Nucleases. Michael C. Holmes, Sangamo BioSciences,
Inc.
Friday, June 24, 2005. Podium presentation.
#841: Towards Gene Knock Out Therapy For AIDS/HIV: Targeted Disruption of
CCR5 Using Engineered Zinc Finger Protein Nucleases. Y. Jouvenot,
Sangamo BioSciences, Inc.
Saturday, June 25, 2005. Podium presentation.
Additional information about the 3rd Annual Meeting of the ISSCR is
available at: www.isscr.org.
Zinc Finger DNA Binding Proteins
Zinc Finger DNA-binding Proteins (ZFPs) are a naturally occurring class of
DNA binding proteins. The DNA recognition and binding function of ZFPs can be
engineered and thus directed to a targeted sequence of DNA. This permits the
delivery of a variety of functional domains to a gene-specific location. ZFPs
are being developed for two significant therapeutic applications: gene
regulation and gene modification. In the case of therapeutic gene regulation,
ZFPs are being engineered to either turn on therapeutically beneficial genes or
turn off the expression of disease-causing genes. For gene modification, ZFPs
are being used in combination with a DNA cutting enzyme (endonuclease)
functional domain to generate ZFNs that facilitate the correction of mutant gene
sequences that cause disease or the disruption of genes that facilitate disease
progression.
About Sangamo
Sangamo BioSciences, Inc. is focused on the research and development of
novel DNA-binding proteins for therapeutic gene regulation and modification. The
most advanced ZFP Therapeutic(TM) development programs are currently in Phase I
clinical trials for evaluation of safety in patients with peripheral artery
disease and diabetic neuropathy. Other therapeutic development programs are
focused on ischemic heart disease, congestive heart failure, cancer, neuropathic
pain, and infectious and monogenic diseases. Sangamo's core competencies enable
the engineering of a class of DNA-binding proteins known as zinc finger
DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA
sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can
control gene expression and, consequently, cell function. Sangamo is also
developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene
modification as a treatment and possible cure for a variety of monogenic
diseases, such as sickle cell anemia, and for infectious diseases such as HIV.
For more information about Sangamo, visit the company's web site at
http://www.sangamo.com/ or http://www.expressinglife.com/ .
This press release may contain forward-looking statements based on Sangamo's
current expectations. These forward-looking statements include, without
limitation, references to the research and development of novel ZFP TFs and
ZFNs, clinical trials and therapeutic applications of Sangamo's ZFP technology
platform. Actual results may differ materially from these forward- looking
statements due to a number of factors, including technological challenges,
Sangamo's ability to develop commercially viable products and technological
developments by our competitors. See the company's SEC filings, and in
particular, the risk factors described in the company's Annual Report on Form
10-K and its most recent 10-Q. Sangamo assumes no obligation to update the
forward-looking information contained in this press release.
SOURCE Sangamo BioSciences, Inc.
-0- 06/21/2005
/CONTACT: Elizabeth Wolffe, Ph.D. of Sangamo BioSciences, Inc.,
+1-510-970-6000, ext. 271, or ewolffe@sangamo.com; or media, Justin Jackson,
+1-212-213-0006, or jjackson@burnsmc.com, or investors, John Cummings,
+1-415-352-6262, both of Burns McClellan, Inc., for Sangamo BioSciences, Inc./
/Web site: http://www.sangamo.com /